Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder

NCT01716624 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's